CARISMA Therapeutics announces FDA clearance of IND application for first-ever engineered macrophage immunotherapy27. July 2020|In Portfolio News|By eazee-designstudioCARISMA Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for the Company’s lead product candidate, CT-0508, an anti-human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). Under this IND, CARISMA intends to initiate its Phase 1, first-in-human, multi-center study in patients with recurrent or metastatic HER2 overexpressing solid tumors after failure of approved HER2 targeted agents. PrevNext
